Antibody directed delivery for treatment of cancer: Antibody drug conjugates and immunotoxins

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 3-22

  Trail, Pamela A ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973351563     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_1     Document Type: Chapter

References (89)

1. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
2. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
3. Jakobovits A (1998) The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Expert Opin Investig Drugs 7:607-614
4. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125
5. Goldenberg DM, Sharkey RM (2010) Radioactive antibodies: a historical review of selective targeting and treatment of cancer. Hosp Pract (Minneap) 38:82-93
6. Steiner M, Neri D (2011) Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 17:6406-6416
7. Frey K, Zivanovic A, Schwager K, Neri D (2011) Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb) 3:468-478
8. Halin C, Niesner U, Villani ME, Zardi L, Neri D (2002) Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 102:109-116
9. Weldon JE, Pastan I (2011) A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278:4683-4700
10. Lorberboum-Galski H (2011) Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 8:605-621
11. Choudhary S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16:495-503
12. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM et al (1993) Cure of xeno-grafted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215
13. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53:3336-3342
14. Liu C, Chari RV (1997) The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin Investig Drugs 6:169-172
15. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
16. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I et al (2011) A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 154:471-476
17. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM (2011) SAR3419: an anti-CD 19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 17:6448-6458
18. Gerber HP, Senter PD, Grewal IS (2009) Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 1:247-253
19. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M (1997) Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031-1044
20. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634
21. Baccala A, Sercia L, Li J, Heston W, Zhou M (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70:385-390
22. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G et al (2009) Prostate- specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40:1754-1761
23. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ (2004) A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64:7995-8001
24. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26:2147-2154
25. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF et al (2006) Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate- specific membrane antigen. Clin Cancer Res 12:2591-2596
26. Wang X, Ma D, Olson WC, Heston WD (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10:1728-1739
27. Vitetta ES, Thorpe PE (1991) Immunotoxins containing ricin or its A chain. Semin Cell Biol 2:47-58
28. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I (1989) Arecombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394-397
29. Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90:7538-7542
30. Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C, Fogli M et al (2000) In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 110:351-361
31. Rosenblum M (2004) Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma. Adv Pharmacol 51:209-228
32. Stirpe F (2004) Ribosome-inactivating proteins. Toxicon 44:371-383
33. Kreitman RJ, Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 7:1301-1311
34. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA (1991) An immuno- toxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 51:6236-6242
35. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ et al (1988) Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 48:6396-6403
36. Ghetie V, Vitetta ES (2001) Chemical construction of immunotoxins. Mol Biotechnol 18:251-268
37. Ghetie V, Vitetta E (1994) Immunotoxins in the therapy of cancer: from bench to clinic. Pharmacol Ther 63:209-234
38. Blakey DC, Watson GJ, Knowles PP, Thorpe PE (1987) Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 47:947-952
39. Winkler U, Gottstein C, Schon G, Kapp U, Wolf J, Hansmann ML et al (1994) Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 83:466-475
40. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES et al (2003) Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 14:729-736
41. Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES (2003) Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17:334-338
42. Shapira A, Benhar I (2010) Toxin-based therapeutic approaches. Toxins (Basel) 2:2519-2583
43. Dosio F, Brusa P, Cattel L (2011) Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 3:848-883
44. Rosenblum MG, Barth S (2009) Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 15:2676-2692
45. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG (2003) Targeted delivery of human pro- apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2:1341-1350
46. Mathew M, Verma RS (2009) Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 100:1359-1365
47. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105:11311-11316
48. Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R (2011) Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma 52(Suppl 2):87-90
49. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC (2009) Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 32:574-584
50. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15:5274-5279
51. Dubowchik GM, Walker MA (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83:67-123
52. Trail PA, Bianchi AB (1999) Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 11:584-588
53. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
54. Katz J, Janik JE, Younes A (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res 17:6428-6436
55. DeFrancesco L (2011) Seattle Genetics rare cancer drug sails through accelerated approval. Nat Biotechnol 29:851-852
56. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y et al (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028-4037
57. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K et al (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101-111
58. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
59. Smyth MJ, Pietersz GA, McKenzie IF (1987) The mode of action of methotrexate-monoclonal antibody conjugates. Immunol Cell Biol 65(Pt 2):189-200
60. Ghose T, Ferrone S, Blair AH, Kralovec Y, Temponi M, Singh M et al (1991) Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunol Immunother 34:90-96
61. Elias DJ, Kline LE, Robbins BA, Johnson HC Jr, Pekny K, Benz M et al (1994) Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med 150:1114-1122
62. Schrappe M, Bumol TF, Apelgren LD, Briggs SL, Koppel GA, Markowitz DD et al (1992) Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 52:3838-3844
63. Petersen BH, DeHerdt SV, Schneck DW, Bumol TF (1991) The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res 51:2286-2290
64. Yang HM, Reisfeld RA (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA 85:1189-1193
65. Trail PA, King HD, Dubowchik GM (2003) Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52:328-337
66. Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ, Hall TC (1994) Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol Immunother 38:92-98
67. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D et al (1992) Antigen- specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 52:5693-5700
68. King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ et al (1999) Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem 10:279-288
69. King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA et al (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem 45: 4336-4343
70. Shih LB, Goldenberg DM, Xuan H, Lu H, Sharkey RM, Hall TC (1991) Anthracycline immu- noconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. Cancer Res 51:4192-4198
71. Saleh MN, LoBuglio AF, Trail PA (1998) Immunoconjugate therapy of solid tumors: studies with BR96-doxorubicin. In: Grossbard ML (ed) Monoclonal antibody-based therapy of cancer, Ith edn. Marcel Dekker, Inc., New York, pp 397-416
72. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496
73. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H et al (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452
74. Jurcic JG (2012) What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep 7:65-73
75. DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK (2011) Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol 67:741-749
76. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immuno- conjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28:2085-2093
77. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
78. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF et al (2003) cAC10- vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465
79. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
80. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H et al (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9:2700-2713
81. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA et al (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52:127-131
82. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K et al (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13:855-869
83. Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA et al (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19:1960-1963
84. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888-897
85. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M et al (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367-9374
86. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS et al (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14:6171-6180
87. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1 an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
88. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W et al (2010) Phase I study of trastu- zumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2- positive metastatic breast cancer. J Clin Oncol 28:2698-2704
89. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405